Ocugen, Inc/$OCGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Ocugen, Inc
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform, Inhaled Mucosal Vaccine Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
Ticker
$OCGN
Sector
Primary listing
Employees
95
Headquarters
Website
Ocugen, Inc Metrics
BasicAdvanced
$500M
-
-$0.20
3.85
-
Price and volume
Market cap
$500M
Beta
3.85
52-week high
$1.90
52-week low
$0.52
Average daily volume
7M
Financial strength
Current ratio
1.828
Quick ratio
1.502
Long term debt to equity
1,047.51
Total debt to equity
1,075.459
Interest coverage (TTM)
-27.99%
Profitability
EBITDA (TTM)
-52.166
Gross margin (TTM)
-622.13%
Net profit margin (TTM)
-1,197.71%
Operating margin (TTM)
-1,161.02%
Revenue per employee (TTM)
$50,000
Management effectiveness
Return on assets (TTM)
-73.29%
Return on equity (TTM)
-569.99%
Valuation
Price to revenue (TTM)
97.052
Price to book
153.18
Price to tangible book (TTM)
153.2
Price to free cash flow (TTM)
-8.822
Free cash flow yield (TTM)
-11.34%
Free cash flow per share (TTM)
-0.181
Growth
Revenue change (TTM)
-34.55%
Earnings per share change (TTM)
1.86%
3-year earnings per share growth (CAGR)
-13.87%
What the Analysts think about Ocugen, Inc
Analyst ratings (Buy, Hold, Sell) for Ocugen, Inc stock.
Bulls say / Bears say
Ocugen will present its innovative modifier gene therapy platform, including Phase 3 data for OCU400, the Phase 2/3 program for OCU410ST, and Phase 2 results for OCU410 at ARVO 2025 and Retina World Congress, highlighting strong clinical progress.
The first patient was dosed in the Phase 2/3 GARDian3 trial for OCU410ST in Stargardt disease on July 18, 2025, marking an important late-stage milestone for a key pipeline candidate.
Ocugen signed a binding term sheet for exclusive Korean licensing rights to OCU400, unlocking up to $11 million in upfront and milestone payments and opening new commercialization opportunities.
Cash, cash equivalents, and restricted cash were only $27.3 million as of June 30, 2025, providing funding into Q1 2026 and indicating a risk of near-term dilutive financing.
The accumulated deficit reached $370.3 million as of June 30, 2025, reflecting large historical losses and ongoing financial challenges.
Lead pipeline assets face long development timelines, with OCU400's BLA/MAA filings not expected until mid-2026 and OCU410ST's BLA planned for 2027, delaying possible revenue and raising regulatory risk.
Data summarised monthly by Lightyear AI. Last updated on 11 Oct 2025.
Ocugen, Inc Financial Performance
Revenues and expenses
Ocugen, Inc Earnings Performance
Company profitability
Ocugen, Inc News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Ocugen, Inc stock?
Ocugen, Inc (OCGN) has a market cap of $500M as of October 19, 2025.
What is the P/E ratio for Ocugen, Inc stock?
The price to earnings (P/E) ratio for Ocugen, Inc (OCGN) stock is 0 as of October 19, 2025.
Does Ocugen, Inc stock pay dividends?
No, Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders as of October 19, 2025.
When is the next Ocugen, Inc dividend payment date?
Ocugen, Inc (OCGN) stock does not pay dividends to its shareholders.
What is the beta indicator for Ocugen, Inc?
Ocugen, Inc (OCGN) has a beta rating of 3.85. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.